Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C128799> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- NCIT_C128799 IAO_0000115 "An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect." @default.
- NCIT_C128799 NCIT_A32 NCIT_C1909 @default.
- NCIT_C128799 NCIT_A7 NCIT_C17319 @default.
- NCIT_C128799 NCIT_NHC0 "C128799" @default.
- NCIT_C128799 NCIT_P106 "Amino Acid, Peptide, or Protein" @default.
- NCIT_C128799 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C128799 NCIT_P107 "Trastuzumab Deruxtecan" @default.
- NCIT_C128799 NCIT_P108 "Trastuzumab Deruxtecan" @default.
- NCIT_C128799 NCIT_P208 "CL509598" @default.
- NCIT_C128799 NCIT_P210 "1826843-81-5" @default.
- NCIT_C128799 NCIT_P302 "adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH ) breast cancer; unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 HER2 (ERBB2) mutations." @default.
- NCIT_C128799 NCIT_P319 "5384HK7574" @default.
- NCIT_C128799 NCIT_P322 "CTRP" @default.
- NCIT_C128799 NCIT_P322 "FDA" @default.
- NCIT_C128799 NCIT_P322 "GDC" @default.
- NCIT_C128799 NCIT_P329 "783025" @default.
- NCIT_C128799 NCIT_P330 "783025" @default.
- NCIT_C128799 NCIT_P375 "Anti-HER2 ADC DS-8201a" @default.
- NCIT_C128799 NCIT_P375 "Trastuzumab Deruxtecan" @default.
- NCIT_C128799 NCIT_P399 "783025" @default.
- NCIT_C128799 normalizedInformationContent "95.413332725061409" @default.
- NCIT_C128799 referenceCount "2" @default.
- NCIT_C128799 hasExactSynonym "DS-8201" @default.
- NCIT_C128799 hasExactSynonym "DS-8201a" @default.
- NCIT_C128799 hasExactSynonym "Enhertu" @default.
- NCIT_C128799 hasExactSynonym "Fam-trastuzumab Deruxtecan-nxki" @default.
- NCIT_C128799 hasExactSynonym "TRASTUZUMAB DERUXTECAN" @default.
- NCIT_C128799 hasExactSynonym "Trastuzumab Deruxtecan" @default.
- NCIT_C128799 hasExactSynonym "WHO 10516" @default.
- NCIT_C128799 inSubset NCIT_C116977 @default.
- NCIT_C128799 inSubset NCIT_C116978 @default.
- NCIT_C128799 inSubset NCIT_C128784 @default.
- NCIT_C128799 inSubset NCIT_C157711 @default.
- NCIT_C128799 inSubset NCIT_C157712 @default.
- NCIT_C128799 inSubset NCIT_C176424 @default.
- NCIT_C128799 inSubset NCIT_C177537 @default.
- NCIT_C128799 inSubset NCIT_C63923 @default.
- NCIT_C128799 type Class @default.
- NCIT_C128799 isDefinedBy ncit.owl @default.
- NCIT_C128799 label "Trastuzumab Deruxtecan" @default.
- NCIT_C128799 subClassOf NCIT_C128799 @default.
- NCIT_C128799 subClassOf NCIT_C129821 @default.
- NCIT_C128799 subClassOf NCIT_C129823 @default.
- NCIT_C128799 subClassOf NCIT_C1512 @default.
- NCIT_C128799 subClassOf NCIT_C155712 @default.
- NCIT_C128799 subClassOf NCIT_C163758 @default.
- NCIT_C128799 subClassOf NCIT_C163760 @default.
- NCIT_C128799 subClassOf NCIT_C1908 @default.
- NCIT_C128799 subClassOf NCIT_C1909 @default.
- NCIT_C128799 subClassOf NCIT_C274 @default.
- NCIT_C128799 subClassOf NCIT_C307 @default.
- NCIT_C128799 subClassOf NCIT_C308 @default.